Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

AstraZeneca PLC (AZN) - Stock Price & Dividends

Exchange: London Exchange • Country: United Kingdom • Currency: GBX • Type: Common Stock • ISIN: GB0009895292

AstraZeneca PLC, listed on the London Stock Exchange as AZN, is a biopharmaceutical company that focuses on developing, manufacturing, and selling prescription medicines. In addition to its widely known products like Tagrisso, Imfinzi, and Lynparza, the company offers a range of medications for various health conditions including cardiovascular, renal, metabolism, and oncology.

With an extensive product portfolio that includes Faslodex, Brilinta, and Symbicort, AstraZeneca PLC caters to healthcare providers worldwide. The company's offerings such as Vaxzevria, Synagis, and Ultomiris play a vital role in addressing conditions like Covid-19 and rare diseases, demonstrating its commitment to global health.

Operating in key regions across the globe, namely the United Kingdom, Europe, Americas, Asia, Africa, and Australasia, AstraZeneca PLC serves both general practitioners and specialists through its network of distributors and local offices. The company's collaborative efforts with partners like Neurimmune AG highlight its dedication to advancing medical innovation and enhancing patient care.

Established in 1992 as Zeneca Group PLC before rebranding in 1999, AstraZeneca PLC is headquartered in Cambridge, UK, underscoring its British roots and commitment to pioneering healthcare solutions. For more information on AstraZeneca PLC and its initiatives, visit their official website: https://www.astrazeneca.com

Drawdown (Underwater) Chart

Overall Trend and Yearly Seasonality

AZN Stock Overview

Market Cap in USD	2,073m
Sector	Healthcare
Industry	Drug Manufacturers - General
GiC SubIndustry	Pharmaceuticals
TER	0.00%
IPO / Inception	1993-05-12

AZN Stock Ratings

Growth 5y	6.85
Fundamental	51.1
Dividend	6.32
Rel. Performance vs Sector	-0.65
Analysts	-
Fair Price Momentum	11417.74 GBX
Fair Price DCF	118.47 GBX

AZN Dividends

Yield 12m	2.01%
Yield on Cost 5y	4.42%
Dividends CAGR 5y	1.41%
Payout Consistency	98.2%

AZN Growth Ratios

Growth 12m	4.66%
Growth Correlation 12m	-32%
Growth Correlation 3m	61%
CAGR 5y	18.38%
Sharpe Ratio 12m	-0.02
Alpha vs SP500 12m	-5.45
Beta vs SP500 5y weekly	0.26
ValueRay RSI	99.76
Volatility GJR Garch 1y	22.84%
Price / SMA 50	14.7%
Price / SMA 200	15.39%
Current Volume	4164.7k
Average Volume 20d	2328.8k

External Links for AZN Stock

Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle

What is the price of AZN stocks?
As of April 26, 2024, the stock is trading at GBX 12026.00 with a total of 4,164,664 shares traded.
Over the past week, the price has changed by +10.19%, over one month by +15.70%, over three months by +16.91% and over the past year by +0.00%.

What is the forecast for AZN stock price target?
According to ValueRays Forecast Model, AZN AstraZeneca PLC will be worth about 12436.2 in April 2025. The stock is currently trading at 12026.00. This means that the stock has a potential upside of +3.41%.

Issuer	Forecast	Upside
Wallstreet Target Price	130.3	-98.9
Analysts Target Price	-	-
ValueRay Target Price	12436.2	3.41

A Look into AstraZeneca PLC: From Origins to Global Pharma Leader

History of AstraZeneca

AstraZeneca, a global biopharmaceutical juggernaut, originated from the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group. Since its inception, AstraZeneca has focused on developing medications in oncology, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory diseases. This merger was not just a fusion of names but of vast research prowess and a rich portfolio of innovative medicines.

Core Business

AstraZeneca's core lies in discovering, developing, and commercializing prescription medicines. Primarily, their work revolves around three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory & Immunology. In oncology, AstraZeneca has made significant strides, providing innovative treatments that have changed the lives of many patients. Their dedication to cardiovascular and metabolic diseases has also led to the development of leading medicines aimed at combating these conditions. Moreover, their respiratory portfolio is robust, addressing asthma and chronic obstructive pulmonary disease (COPD) among others.

Side Businesses and Collaborations

Beyond their primary focus, AstraZeneca engages in various other businesses, including the manufacturing of hospital and dental supplies. They’ve also established several strategic collaborations to bolster their research and development capabilities, partnering with academic institutions, biotechnology companies, and government entities. These collaborations aim to accelerate the delivery of innovative treatments to patients.

Current Market Status

As of the latest financial reports, AstraZeneca continues to show robust performance in the global market. Their strategic acquisitions and partnerships have expanded their pipeline and market presence significantly. Despite the challenges posed by global market fluctuations and the constantly evolving healthcare landscape, AstraZeneca has maintained a strong growth trajectory, thanks to their continuous innovation and the development of high-demand medications. The company's commitment to addressing unmet medical needs continues to drive its success, making it a formidable player in the pharmaceutical industry.